Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$9.3 - $16.6 $388,767 - $693,929
41,803 Added 5.75%
768,825 $8.84 Million
Q2 2023

Aug 14, 2023

BUY
$7.66 - $16.46 $152,349 - $327,372
19,889 Added 2.81%
727,022 $12 Million
Q1 2023

May 15, 2023

BUY
$1.46 - $12.54 $1.03 Million - $8.81 Million
702,770 Added 16107.49%
707,133 $6.31 Million
Q4 2022

Feb 14, 2023

SELL
$0.41 - $4.54 $3,178 - $35,198
-7,753 Reduced 63.99%
4,363 $9,000
Q3 2022

Nov 14, 2022

BUY
$1.06 - $2.96 $12,842 - $35,863
12,116 New
12,116 $13,000

Others Institutions Holding AMAM

About Ambrx Biopharma Inc.


  • Ticker AMAM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,618,400
  • Market Cap $1.08B
  • Description
  • Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...
More about AMAM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.